Myrobalan Therapeutics secures funding for CNS drug development

Myrobalan Therapeutics has secured $24m in a Series A funding round to develop CNS therapeutics with restorative potential.

Jan 11, 2024 - 18:00

Myrobalan Therapeutics secures funding for CNS drug development

Myrobalan Therapeutics has secured $24m in a Series A funding round to develop CNS therapeutics with restorative potential.

Read the original article

Tags:

Previous Article

GSK’s Nucala for severe eosinophilic asthma gains approval in China

Risk adjusted net present value: What is the current valuation of Lumos Pharma’s...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

Jazz’s cannabidiol therapy flunks in Japanese Phase III...

Aug 25, 2024

Agios sells vorasidenib US royalties for $905m

Agios sells vorasidenib US royalties for $905m

May 31, 2024

STAT+: Not-for-profit CommonSpirit Health paid its CEO $35 million in 2021

STAT+: Not-for-profit CommonSpirit Health paid its CEO ...

Aug 15, 2023